GlaxoSmithKline’s chief executive has opened the possibility of the group’s being broken up in the future as he pushes through a sweeping overhaul of Britain’s biggest drugmaker.
Sir Andrew Witty said GSK had the option to spin off its consumer healthcare business if a time came when it offered more value as a standalone company.
He made clear that there were no such plans in the near term but, by raising it as a possibility, he signalled his openness to further restructuring at a time of mounting challenges for the company.
您已阅读32%（529字），剩余68%（1112字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。